# PDE7 as a Precision Target: Bridging Disease Modulation and Potential PET Imaging for Translational Medicine

## TL;DR

This paper explores PDE7 as a key target for treating diseases and monitoring them through PET imaging.

## Contribution

The paper highlights recent developments in selective PDE7 inhibitors and their potential for both therapy and PET imaging.

## Key findings

- PDE7 inhibitors show high selectivity and potent biological effects.
- Radiolabeled PDE7 inhibitors could enable noninvasive disease monitoring via PET imaging.

## Abstract

Phosphodiesterase
7 (PDE7) regulates cAMP-PKA signaling
and plays
a crucial role in immune function, neuroprotection, and inflammation.
Dysregulated PDE7 activity is linked to neurodegenerative, autoimmune,
and metabolic disorders, making it a promising therapeutic target.
Recent advancements in PDE7 inhibitors, particularly pyrimidinone-based
compounds, have shown high selectivity and potent biological effects.
Beyond therapeutics, radiolabeled PDE7 inhibitors offer potential
for PET imaging, enabling noninvasive disease monitoring and treatment
assessment.